GI Pancreatic - Metastatic

KNIGHT CANCER Institute
OHSU

Localized

NeoAdjuvant

- IRB #19211 A Feasibility Study to Assess a Window of Opportunity Strategy for Targeted PARP or MEK Inhibition in Patients with Pancreatic Ductal Adenocarcinoma
- IRB #21614 NeoOptimize: An Open-Label, Phase II Trial To Assess The Efficacy Of Adaptive Switching Of mFolfirinox Or Gemcitabine/Nab-Paclitaxel As A Neoadjuvant Strategy For Patients With Resectable And Borderline Resectable Pancreatic Cancer.

Adjuvant

- IRB# 17751 Trans(Intra)-arterial Gemcitabine vs. Continuation of IV Gemcitabine and Nab-Paclitaxel following Radiotherapy for Locally Advanced Pancreatic Cancer

Metastatic

First Line Treatment for Advanced or Metastatic Pancreatic Cancer

- IRB#15588 New study will be available soon.
- IRB# 17094 A Phase Ib/II, Open-Label, Multicenter, Randomized Umbrella Study Evaluating the Efficacy and Safety of Multiple Immunotherapy-Based Treatment Combination in Patients with Metastatic Pancreatic Ductal Adenocarcinoma (Morpheus-Pancreatic Cancer)
- IRB#21790 An open-label, randomised, multicentre, phase III study of irinotecan liposome injection, oxaliplatin, 5-fluorouracil/leucovorin versus nab-paclitaxel plusgemcitabine in subjects who have not previously received chemotherapy for metastatic adenocarcinoma of the pancreas

Second Line Treatment for Advanced or Metastatic Pancreatic Cancer

- IRB# 17094 A Phase Ib/II, Open-Label, Multicenter, Randomized Umbrella Study Evaluating the Efficacy and Safety of Multiple Immunotherapy-Based Treatment Combination in Patients with Metastatic Pancreatic Ductal Adenocarcinoma (Morpheus-Pancreatic Cancer)

Third Line Treatment for Advanced or Metastatic Pancreatic Cancer

- IRB# 17094 A Phase Ib/II, Open-Label, Multicenter, Randomized Umbrella Study Evaluating the Efficacy and Safety of Multiple Immunotherapy-Based Treatment Combination in Patients with Metastatic Pancreatic Ductal Adenocarcinoma

Cross-Disease Trials:

- **IRB# TBD** EAY131 (MATCH)
- **IRB# 20679** Serial Measurements of Molecular and Architectural Responses to Therapy (SMMART) Trial: Adaptive Clinical Treatment

http://www.ohsu.edu/research/rda/so/knight.php

Key

- Open for Enrollment
- In Development
- Enrollment on Hold

3/1/2021